Key Takeaways
- IBI Ag has completed a $10 million Series A funding round, marking a major milestone in its development of antibody-based bioinsecticides.
- The round was led by Corteva through its Corteva Catalyst platform, with participation from The Trendlines Group, Iron Nation, Consensus Business Group (CBG), and support from the Israel Innovation Authority, alongside new investors Bandera Capital and First Imagine Ventures.
- Funding will accelerate product development, regulatory progress, and commercialization of IBI Ag’s next-generation biological pest control solutions.
- The company’s proprietary platform uses single-domain antibodies (nanobodies) to create targeted, eco-friendly bioinsecticides that preserve beneficial insects.
- The investment highlights growing global recognition of IBI Ag’s innovative approach to sustainable crop protection.
IBI Ag Secures $10 Million to Scale Next-Generation Biological Crop Protection
IBI Ag, a biotechnology company pioneering antibody-based bioinsecticides, has successfully closed its Series A funding round at $10 million. The investment underscores increasing global interest in biological pest control technologies that combine effectiveness with a lower ecological footprint.
The round was led by Corteva through its Corteva Catalyst platform, joined by The Trendlines Group (SGX:42T), Iron Nation, Consensus Business Group (CBG), and a grant from the Israel Innovation Authority. New investors Bandera Capital and First Imagine Ventures also participated, contributing to the completion of the round.
“We’re proud to have the continued confidence of our investors and to welcome Bandera Capital and First Imagine Ventures to the IBI Ag family,” said Arnon Heyman, CEO of IBI Ag. “With the completion of our Series A, we are well positioned to bring our novel biological solutions closer to farmers worldwide, supporting both productivity and sustainability.”
Revolutionizing Pest Control with Antibody-Based Bioinsecticides
IBI Ag’s proprietary platform leverages single-domain antibodies (nanobodies) — adapted from the pharmaceutical field and optimized for agricultural use — to deliver highly selective, safe, and effective pest control. These bioinsecticides introduce new modes of action to protect crops from both sucking and chewing insects, while minimizing impact on non-target and beneficial species.
This innovation represents a breakthrough in biological crop protection, combining precision targeting with sustainability. By reducing the need for conventional chemical insecticides, IBI Ag’s technology aims to support regenerative agriculture and environmental stewardship in farming systems worldwide.
IBI Ag's Strategic Partnership with Corteva Catalyst
The collaboration with Corteva reflects a shared commitment to advancing early-stage agricultural innovation. Through its Corteva Catalyst platform, the company partners with startups developing technologies that improve farmer resilience, productivity, and sustainability.
“The collaboration between IBI Ag and Corteva is a clear example of how working together can deliver innovation that increases performance and provides more sustainable solutions in crop protection,” said Tom Greene, Senior Director at Corteva and Global Leader for Corteva Catalyst. “We are excited to continue exploring the development of next-generation biologicals and naturally inspired solutions as IBI Ag advances toward commercialization.”
Accelerating Commercialization and Global Reach
With this latest funding, IBI Ag plans to expand its R&D programs, pursue regulatory approvals, and advance commercial partnerships to bring its bioinsecticide products to market. The company’s solutions target high-value crops vulnerable to insect damage, providing an alternative to synthetic pesticides in both open-field and controlled-environment agriculture.
The Series A milestone reflects wider investor confidence in biological crop protection as a key driver of sustainable farming practices, aligning with global initiatives to reduce chemical pesticide use and promote biodiversity-friendly solutions.
